Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Falls Church, Virginia Clinical Trials

A listing of Falls Church, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (220) clinical trials

Mechanism of Action Underlying Ketamine s Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Objective Work by our group and others has demonstrated that a single intravenous dose of the glutamatergic modulator ketamine consistently produces rapid (within two hours), robust, and relatively sustained (approximately one to two weeks) antidepressant effects in patients with treatment-resistant major depressive disorder (MDD) and bipolar depression. Although ketamine is ...

Phase

8.96 miles

Learn More »

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Background Multiple myeloma (MM) is a nearly always incurable malignancy of plasma cells. T cells can be genetically modified to express chimeric antigen receptors (CARs) that target malignancy-associated antigens. SLAMF7 is highly and uniformly expressed on MM cells but is absent on normal tissues except for some leukocytes, including a ...

Phase

8.96 miles

Learn More »

Safety Tolerability Pharmacokinetics and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects With Stable Sickle Cell Disease

Sickle cell disease (SCD) is a multisystem disorder associated with episodes of acute clinical events and progressive organ damage. Episodic pain, triggered by micro-vasoocclusion induced by sickled red blood cells, is the most common acute complication and the leading cause of hospitalization. Management strategies for SCD have evolved very slowly, ...

Phase

8.96 miles

Learn More »

Nivolumab in Treating Patients With Autoimmune Disorders or Advanced Metastatic or Unresectable Cancer

PRIMARY OBJECTIVES: I. To assess the overall safety, including the incidence of dose-limiting toxicity (DLT), and other toxicities associated with the use of the anti-programmed death 1 (PD-1) antibody nivolumab in patients with varying severity of dermatomyositis (DM)/systemic sclerosis (SSc), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease ...

Phase

8.96 miles

Learn More »

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Background Pancreatic cancer is the fourth most common cause of cancer death in the United States, claiming more than 40,000 lives each year. Incidence nearly equals mortality with just 6% of participants living five years beyond their diagnosis. Most patients are diagnosed at an advanced stage, but even patients with ...

Phase

8.96 miles

Learn More »

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

A Phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer. Patients with metastatic or unresectable locally advanced malignant solid tumors will be enrolled and treated according to a 3+3 dose escalation scheme. Up to 3 dose levels will be explored. Patients will receive ...

Phase

8.96 miles

Learn More »

Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

Idiopathic CD4 lymphopenia (ICL) is characterized by persistent low CD4 counts, frequently in combination with CD8, natural killer, or B cell lymphopenia. It is considered a heterogeneous disorder with manifestations that can include autoimmunity, invasive fungal infections or infections with human papillomavirus, and malignancies typically related to infections. The exact ...

Phase

8.96 miles

Learn More »

S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)

RYR1- related myopathy comprises a group of rare neuromuscular diseases. Affected individuals generally present with delayed motor milestones, muscle weakness, impaired ambulation, and, in severe cases, scoliosis, ophthalmoplegia, and respiratory distress all due to skeletal muscle weakness. Causative variants in RYR1, which encodes the major calcium (Ca2+) release channel in ...

Phase

8.96 miles

Learn More »

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Background Improved treatments for a variety of treatment-resistant malignancies including B-cell lymphomas, and chronic lymphocytic leukemia (CLL) and Hodgkin lymphoma are needed. A particular need is development of new treatments for chemotherapy-refractory B-cell malignancies. T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated ...

Phase

8.96 miles

Learn More »

Trial to Evaluate CIS43LS in Healthy Adults

Title: VRC 612: A Phase 1, Dose Escalation, Open-Label Clinical Trial with Experimental Controlled Human Malaria Infections (CHMI) to Evaluate the Safety and Protective Efficacy of an Anti- Malaria Human Monoclonal Antibody, VRC-MALMAB0100-00-AB (CIS43LS), in Healthy, Malaria-Na(SqrRoot) ve Adults. Design: This is the first study of the VRC-MALMAB0100-00-AB (CIS43LS) monoclonal ...

Phase

8.96 miles

Learn More »